Press releases
- Alkermes to Report Second Quarter Financial Results on July 24, 2024
- Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024
- Alkermes to Participate in Two Upcoming Investor Conferences
- Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024
- Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
- Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
- Alkermes plc Reports First Quarter 2024 Financial Results
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | 20.18 |
---|---|
High | 20.18 |
Low | 19.75 |
Bid | 19.82 |
Offer | 19.92 |
Previous close | 19.75 |
Average volume | -- |
---|---|
Shares outstanding | 169.22m |
Free float | 167.09m |
P/E (TTM) | 7.03 |
Market cap | 4.16bn USD |
EPS (TTM) | 3.50 USD |
Data delayed at least 15 minutes, as of Oct 30 2019.
More ▼